Silvia Grazzini

Dr. Silvia Grazzini

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2024 in Frontiers in Medicine
Verified
Journal Article
Open access
ECEdoardo Conticini
Edoardo Conticini
PFPaolo Falsetti
Paolo Falsetti
SKSuhel Gabriele Al Khayyat
Suhel Gabriele Al Khayyat
SGSilvia Grazzini
Silvia Grazzini
CBCaterina Baldi
Caterina Baldi
BFBruno Frediani
Bruno Frediani
Objectives: Ultrasound has a paramount role in the diagnostic assessment of giant cell arteritis (GCA); Southend halo score (HS), halo count (HC), and OMERACT GCA Ultrasonography Score (OGUS) are the first quantitative scores proposed in this setting. The aim of this study was therefore to assess the diagnostic accuracy of these scores in a real-life scenario, as well as to evaluate their optimal cutoff, also with respect to disease extent, sex, and age.Methods: We retrospectively collected clinical, serological, and US findings of all patients referred for the first time to our vasculitis clinic in the suspicion of GCA.Results: A total of 79 patients were included, and a definite diagnosis of GCA was made in 43 patients. For OGUS, the ROC curve showed an optimal cut point of 0.81 (sensitivity 79.07% and specificity 97.22%). For HC and HS, the optimal cutoff values were > 1.5 (sensitivity 76.7% and specificity 97.2%) and > 14.5 (sensitivity 74.4% and specificity 97.2%), respectively. No relevant differences were assessed when patients were stratified according to disease extent, age, and sex. Compression sign (CS) was positive in 34 of 38 patients with cranial GCA and negative in all controls and LV-GCA.Conclusion: All three scores display good sensitivity and excellent specificity, although the cutoff was slightly different than proposed. In particular, for OGUS, a threshold of 0.81 could be employed for diagnostic purposes, although it was developed solely for monitoring. Due to its high sensitivity and specificity, CS should be always assessed in all patients referred with a suspicion of cranial GCA.


12 July 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
BPBrunetta Porcelli
Brunetta Porcelli
Miriana D'AlessandroMiriana D'Alessandro
Miriana D'Alessandro
LGLatika Gupta
Latika Gupta
SGSilvia Grazzini
Silvia Grazzini
NVNila Volpi
Nila Volpi
ECEdoardo Conticini
Edoardo Conticini
Background: Anti-cytosolic 5′-nucleotidase 1A (anti-cN1A) antibodies were proposed as a biomarker for the diagnosis of inclusion body myositis (IBM), but conflicting specificity and sensitivity evidence limits its use. Our study aimed to assess the diagnostic accuracy of anti-cN1A in a cohort of patients who underwent a myositis line immunoassay for suspected idiopathic inflammatory myopathies (IIM). We also assessed the agreement between two testing procedures: line immunoassay (LIA) and enzyme-linked immunoassay (ELISA). Materials and methods: We collected retrospective clinical and serological data for 340 patients who underwent a myositis antibody assay using LIA (EUROLINE Autoimmune Inflammatory Myopathies 16 Ag et cN-1A (IgG) line immunoassay) and verification with an anti-cN1A antibody assay using ELISA (IgG) (Euroimmun Lubeck, Germany). Results: The serum samples of 20 (5.88%) patients (15 females, 5 males, mean age 58.76 ± 18.31) tested positive for anti-cN1A using LIA, but only two out of twenty were diagnosed with IBM. Seventeen out of twenty tested positive for anti-cN1A using ELISA (median IQR, 2.9 (1.9–4.18)). Conclusions: Our study suggests excellent concordance between LIA and ELISA for detecting anti-cN1A antibodies. LIA may be a rapid and useful adjunct, and it could even replace ELISA for cN1A assay. However, the high prevalence of diseases other than IBM in our cohort of anti-cN1A-positive patients did not allow us to consider anti-cN1A antibodies as a specific biomarker for IBM.

29 August 2025 in Respiratory Medicine
Verified
Journal Article
Open access
ECEdoardo Conticini
Edoardo Conticini
PCPaolo Cameli
Paolo Cameli
SGSilvia Grazzini
Silvia Grazzini
Miriana D'AlessandroMiriana D'Alessandro
Miriana D'Alessandro
LBLaura Bergantini
Laura Bergantini
BFBruno Frediani
Bruno Frediani
The prevalence of interstitial lung disease (ILD) in ANCA associated vasculitis (AAV) ranges from 13 % to 45 %, and both its definition and management represent a quandary. The occurrence of lung fibrosis and ANCA positivity, particularly in subjects without any other evidence of vasculitis, is far from being clearly interpreted, as well as its proper therapeutic management. In this regard, aim of this study is to assess whether Rituximab (RTX) in association with a low dosage of glucocorticoids (GCs), could be effective also in the treatment of AAV-ILD. We prospectively included all patients referred to our multidisciplinary "Vasculitis with lung involvement clinic" from January 2022 to March 2023 with microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA), ANCA positivity and ILD. All patients were concomitantly evaluated by a rheumatologist and a pneumologist experienced in vasculitis and autoimmune-associated ILD. High resolution computed tomography (HRCT) of the chest was performed at baseline and then after 12 months, while lung function test (LFT), including diffusion lung capacity for CO (DLCO) assessment, at baseline and after 6 and 12 months. For induction of remission, patients were treated with RTX, administered with the two-dose protocol (1000 mg at baseline and after 14 days) approved for rheumatoid arthritis, followed by 500 mg every 6 months. GCs were prescribed and then tapered according to PEXIVAS trial. Eight patients, 3 affected by GPA and 5 by MPA, were included. All but one displayed positivity for anti-MPO and 3 of them did not have any extra-pulmonary sign of vasculitis. At baseline, LFT evidenced a restrictive pattern (mean FVC 83 %) associated with a moderate impairment of diffusion capacity (mean DLCO 54 %). After 6 and 12 months, a stabilization of LFT findings was evidenced, while no sign of progression of ILD was assessed at CT scan. No patient suffered from severe AE, except one who had bacterial pneumonia. All patients but three discontinued GCs. Ours represents the first prospective study specifically designed to evaluate the efficacy of RTX in AAV-ILD. Our findings have displayed that RTX, prescribed in association with a short course of GCs, is able to stabilize imaging features and respiratory functional parameters.

13 January 2025 in Reumatismo
Verified
Journal Article
Open access
PDF file
CRChiara Rizzo
Chiara Rizzo
SGSilvia Grazzini
Silvia Grazzini
ECEdoardo Conticini
Edoardo Conticini
HCHector Chinoy
Hector Chinoy
RDRoberto D’aLessandro
Roberto D’aLessandro
Lidia La BarberaLidia La Barbera
Lidia La Barbera
Objective. Idiopathic inflammatory myopathies (IIM) are rare autoimmune diseases that primarily affect striated muscles; skin, joints, and lungs may be involved with different degrees of severity. Traditional treatment relies on high-dose glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs. Methods. A growing amount of evidence is demonstrating the potential role of novel treatments in the management of IIM. We report our experience with Janus kinase inhibitors (JAKi) in these conditions and review the current evidence for the use of small molecules in real-life clinical practice. Results. A total of 41 papers were retrieved from PubMed, 37 papers concerning IIM and JAKi, and 4 papers concerning IIM and apremilast. Conclusions. An overall good efficacy was evidenced in IIM-associated skin lesions, including rash, ulcers, and calcinosis. If present, muscle and joint involvement demonstrated a good response to therapy, while it was not possible to draw any conclusion about dysphagia. No life-threatening adverse events were reported.

4 April 2026 in Rheumatology
Verified
Journal Article
Closed access
PDF file
MPMaria Rosa Pellico
Maria Rosa Pellico
CBCristina Bochicchio
Cristina Bochicchio
EMElisabetta Miserocchi
Elisabetta Miserocchi
SCSilvia Cavalli
Silvia Cavalli
IMIlaria Magi
Ilaria Magi
NPNicoletta Del Papa
Nicoletta Del Papa
The 2023 International Myositis Assessment and Clinical Studies Group (IMACS) guidelines introduced a standardized risk-stratification model for cancer screening in idiopathic inflammatory myopathies (IIM). However, real-world data on their application remain limited. This study aimed to evaluate the effectiveness of IMACS-based risk stratification in predicting malignancy and assess adherence to cancer screening recommendations in a multicentric Italian IIM cohort. We conducted a multicentre retrospective study including 411 IIM patients from five Italian rheumatology centres, classified into IMACS-defined standard, intermediate, and high-risk groups. Cancer occurrence within three years of IIM diagnosis was assessed. Screening practices prior to the implementation of IMACS guidelines were compared with their recommendations. Logistic regression analysis was used to evaluate the predictive value of IMACS stratification. Among 411 patients, 180 (43.8%) were classified as high-risk, 156 (37.7%) as intermediate-risk, and 75 (18.2%) as standard-risk. Cancer was diagnosed in 9.2% of patients within three years of IIM onset, with high-risk patients significantly more likely to develop malignancy (OR = 4.05, p= 0.026). Anti-TIF1γ (OR = 12.3, p< 0.001) and anti-SAE1 (OR = 11.9, p= 0.012) were independent predictors of cancer. Screening adherence varied, with underutilization of enhanced screening in intermediate-risk patients and a decline in screening over time. The IMACS stratification model effectively predicts cancer risk in IIM. However, real-world screening practices show inconsistencies, particularly in intermediate-risk patients. These findings support the need for optimized, risk-adapted malignancy surveillance in IIM and refinement of current guidelines based on real-world data.